ENJUVIA (estrogens, conjugated synthetic b) by Aspen Surgical is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: treatment of moderate to severe vasomotor symptoms associated with menopause. First approved in 2004.
Drug data last refreshed 5h ago · AI intelligence enriched 5d ago
ENJUVIA is an oral tablet containing conjugated synthetic estrogens (estrone and equilin) approved for treatment of moderate to severe vasomotor symptoms associated with menopause. The drug works by binding to estrogen receptors in target tissues and reducing elevated gonadotropin levels in postmenopausal women. The formulation provides slow, sustained release of active estrogens over several hours.
Product is approaching loss of exclusivity with moderate competitive pressure (30 on competitive index), signaling potential team contraction and transition to lifecycle management focus.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on ENJUVIA at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
Career opportunities on ENJUVIA are concentrated in commercial and regional sales roles, reflecting the mature lifecycle stage. Limited linked job openings (2) indicate a small, stable team focused on market defense rather than growth initiatives.
2 open roles linked to this drug